Recent Updates
Recently added Catalysts

Biomea Fusion, Inc.

BMEAFDA catalysts, PDUFA dates & pipeline intelligence
$0.49
▼ -0.03 · -6.17%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BMEA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.4652W HIGH $2.24
Volume
1.20 M
Value Traded
586.95 K
Short % Float
22.45%
Days to Cover
8.4
-20.12%Week
-41.59%1 Month
-64.89%3 Month
-63.31%6 Month
-91.89%5 Year
-92.9%All Time

Cash Data

Unlock BMEA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
35.47 M
EPS (TTM)
-0.31
P/E Ratio
-
Ent. Value
9.06 M
Total Shares
72.68 M
Float Shares
67.76 M
Insiders
6.76%
Institutions
42.66%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 topline data readout
icovamenib (COVALENT-211)
insulin-deficient type 2 diabetes (T2D) patients not achieving glycemic targets despite antihyperglycemic medications
Phase 2Small MoleculesMetabolic
Unlock every BMEA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BMEA Catalyst Timeline

Dated clinical, regulatory and corporate events for Biomea Fusion, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Biomea Fusion, Inc.

407Total events
14Upcoming
76Tier-1 (high impact)
2021 to 2027Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
BMF-219
T2Enrollment Complete
Subscribe to view catalyst details
BMF-219

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Topline ReadoutBMF-650Clinical Data
Phase 1 GLP-131 results for BMF-650 announced, showing weight reduction and tolerability
obesity/overweightsource ↗
▲Safety Data UpdateBMF-650Clinical Data
BMF-650 Phase 1 safety/tolerability data across five MAD cohorts
obesity/overweightsource ↗
▲PK PD DataBMF-650Clinical Data
BMF-650 Phase 1 PK and one-step titration data
overweight or obese, otherwise healthy adultssource ↗
●R&D DayPresentation
Biomea Fusion conference call and webcast on October 13, 2026
●Equity OfferingCorporate
Biomea Fusion terminates proposed public offering of securities
●Equity OfferingCorporate
Biomea Fusion announced proposed public offering of securities
▲Enrollment CompleteBMF-219Trial
Completion of enrollment in COVALENT-211
insulin-deficient type 2 diabetessource ↗
▲First Patient DosedBMF-219Trial
First participant dosed in OPAL study arm evaluating icovamenib in combination with semaglutide
obesitysource ↗
▲Partnership / LicenseBMF-219Corporate
Research collaboration with University of Leicester initiated
Obesitysource ↗
Unlock the full BMEA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BMEA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-16BMF-650 Phase 1 data presentation Phase 1
Unlock 10 more BMEA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 20%
Micro Cap
(rank 146 of 725)
Percentile Rank
Showing 5 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
icovamenib Small MoleculesNCT07502495Type 2 DiabetesPhase 2 ACTIVE NOT_RECRUITING 124Sep 1, 2027
BMF-219 Small MoleculesCompletedNCT05731544Type 2 Diabetes MellitusPhase 1/2 COMPLETED 443Jul 8, 2025
BMF-219 Small MoleculesCompletedNCT06152042Type 1 Diabetes MellitusPhase 2 COMPLETED 37Jul 18, 2025
BMF-500 Small MoleculesCompletedNCT05918692Acute Myeloid LeukemiaPhase 1 COMPLETED 35Apr 30, 2026
BMF-650 Small MoleculesCompletedNCT07223216ObesityPhase 1 COMPLETED 90Aug 26, 2026
Unlock the BMEA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BMEA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
BMF-650 weight reductionPhase 12026-11-10demonstrated weight reduction over 28 daysRead MoreBiomea Fusion Reports Third Quarter 2026 Financial Results and Corporate HighlightsRead More
Scroll for more · summaries link to the source press release
Unlock every BMEA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BMEA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Erdtmann Rainer MDirector, Officer (See Remarks)Grant/Award 452,512 452,512 held$0.00 04/01/2026
Unlock the full BMEA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
BAKER BROS. ADVISORS 0.1 % (-50 %) 5.63 M 1.45 M -31.15% ( -656.96 K)
Unlock every fund holding BMEA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BMEA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BMEA ownership
Insider and institutional ownership, quarter by quarter.

BMEA Short Interest

Shares sold short, counted twice a month.

22.45%
Short % of Float
of tradable shares sold short
15.2M
Shares Sold Short
-3.2% vs prior count
8.4 High
Days to Cover
trading days of normal volume to buy every short share back
1.8M
Avg Daily Volume
the average used for days to cover
Unlock BMEA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock BMEA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BMEA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BMEA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BMEA ranks across every disease it competes in

Competitive Position is a premium feature
See how BMEA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BMEA News

BMEA
Nov 12, 2026
BMEAConferences/Events

Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion will participate in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and Citi's 2026 Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings to discuss their clinical-stage biopharmaceutical developments. The company focuses on therapies for diabetes and obesity.

Read more →
BMEA
Nov 10, 2026
BMEAPhases
▲ +11.7%on this newsshared move

Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion reported its third quarter 2026 results, highlighting the completion of enrollment in the Phase II COVALENT-211 trial for icovamenib. The company also announced positive Phase I results for BMF-650, which demonstrated weight reduction. Additionally, the cash runway is projected to last into the second quarter of 2027, supporting ongoing clinical trials.

Read more →
BMEA
Nov 10, 2026
BMEAConferences/Events
▼ -8.1%on this newsshared move

Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026

Biomea Fusion announced it will present Phase 1 results for BMF-650, an oral GLP-1 receptor agonist, at ObesityWeek 2026. The conference is scheduled for November 14-17, 2026, in National Harbor, Maryland. The presentation will be led by Dr. Thorsten A. Kirschberg on November 16, 2026.

Read more →
BMEA
Oct 13, 2026
BMEAPhases
▼ -33.8%on this news

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion announced positive Phase 1 results for BMF-650, an oral GLP-1 receptor agonist. The trial showed consistent weight reduction of 1.5% to 3.2% across cohorts, with no severe adverse events. The drug demonstrated good tolerability, even at higher doses, supporting further evaluation. The company plans to continue development and explore strategic partnerships.

Read more →
BMEA
Oct 12, 2026
BMEAPhases
▼ -7.4%on this news· ran to -39% by day 1shared move

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion, Inc. will announce results from its Phase I clinical study of BMF-650, a next-generation oral small-molecule GLP-1 receptor agonist, on October 13, 2026. The company aims to address diabetes and obesity, significant global health challenges. A conference call will follow the announcement to discuss the results.

Read more →
BMEA
Sep 23, 2026
BMEAGeneral
▼ -15.3%on this news

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Biomea Fusion has announced the termination of its proposed public offering of securities due to unfavorable market conditions. The decision was made to protect the interests of the company's stockholders. No securities were sold in connection with the offering, which was initially announced on September 22, 2026.

Read more →
BMEA
Sep 22, 2026
BMEAGeneral
▼ -15.3%on this newsshared move

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion has announced a proposed public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. The company focuses on developing therapies for diabetes and obesity, aiming to provide transformative treatments. However, uncertainties regarding the offering's completion and terms are noted.

Read more →
BMEA
Aug 24, 2026
BMEAPhases
▲ +16.1%on this news· ran to +26% by day 1

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Biomea Fusion has completed enrollment in the COVALENT-211 Phase II trial, evaluating icovamenib for insulin-deficient Type 2 Diabetes patients. The trial enrolled 64 participants and aims to assess glycemic control over a 52-week period. Topline results for the primary endpoint are anticipated in the first quarter of 2027, following promising data from earlier studies.

Read more →
BMEA
Aug 13, 2026
BMEAPhases

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion has initiated a new arm of its OPAL study, dosing the first participant with icovamenib combined with low-dose semaglutide. This study aims to evaluate the effects of this combination on weight loss and various health metrics in individuals who are overweight or obese. The trial will assess whether icovamenib can enhance the efficacy of semaglutide, focusing on broader metabolic health outcomes.

Read more →
BMEA
Aug 5, 2026
BMEAPhases

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion reported its second quarter 2026 financial results, highlighting ongoing enrollment in two Phase II trials for Type 2 diabetes and a Phase I trial for obesity. The company anticipates initial weight reduction data from its BMF-650 trial in Q3 2026. Financially, Biomea reported a net loss of $8.3 million but has a cash runway extending into Q2 2027.

Read more →
BMEA
Jun 5, 2026
BMEAPhases
▼ -7.3%on this news

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion presented promising new clinical and translational data for icovamenib at the ADA 86th Scientific Sessions. The data highlights potential benefits in muscle preservation, fat reduction, and improvements in glycemic control among type 1 and type 2 diabetes patients. Additionally, Biomea announced the expansion of its Phase I BMF-650 study to optimize dosing and enhance weight loss potential. Overall, the findings support icovamenib's broader therapeutic utility in obesity and diabetes management.

Read more →
BMEA
Jun 3, 2026
BMEAPhases
▼ -5.1%on this news· ran to -16% by day 3shared move

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion has announced a collaboration with the University of Leicester to evaluate the effects of icovamenib in combination with semaglutide on obesity. This study, part of the OPAL platform trial, aims to assess improvements in physical function and metabolic outcomes. The trial will begin enrollment in Q3 2026, focusing on individuals who are overweight or obese without type 2 diabetes.

Read more →
BMEA
May 13, 2026
BMEAConferences/Events
▼ -6.3%on this news· ran to -21% by day 3

Biomea Fusion to Participate at Upcoming Investor Conferences - May 12, 2026

Biomea Fusion, Inc. announced its participation in upcoming investor conferences, highlighting its focus on developing therapies for diabetes and obesity. The company aims to address metabolic disorders affecting a large portion of the global population. Webcasts of the events will be available for those unable to attend live.

Read more →
BMEA
May 11, 2026
BMEAPhases

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion reported its first quarter 2026 financial results, highlighting progress in its clinical trials for icovamenib in type 1 and type 2 diabetes. The company successfully completed chronic toxicology studies and initiated two Phase II trials for type 2 diabetes. Additionally, topline data from the Phase II COVALENT-112 trial showed promising results, with a cash runway projected into early 2027.

Read more →
BMEA
May 5, 2026
BMEAConferences/Events

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion announced that three abstracts on icovamenib will be presented at the ADA 86th Scientific Sessions. The presentations will showcase data on the investigational oral menin inhibitor's effects on beta cell function in type 1 and type 2 diabetes. The event will take place from June 5-8, 2026, in New Orleans.

Read more →
BMEA
Apr 28, 2026
BMEAConferences/Events
▼ -11.6%on this newsshared move

COVALENT-112 Topline Results BIOMEA

Biomea Fusion, Inc. has shared forward-looking statements regarding future business and financial performance. The presentation emphasizes the uncertain nature of these predictions, which are influenced by various risks, including regulatory approvals and market dynamics. Specifically, the discussion touches on the investigational therapies for Type 1 Diabetes and the limitations associated with existing treatment options. A focus is placed on the anticipated clinical trials and the goals of restoring beta cell function, although challenges persist in achieving durable therapeutic outcomes.

Read more →
BMEA
Apr 27, 2026
BMEAPhases
▼ -8.5%on this news· ran to -28% by day 3shared move

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion announced positive results from its Phase 2 COVALENT-112 trial, showing a 52% increase in mean C-peptide AUC at Week 12 for patients with type 1 diabetes treated with icovamenib. The treatment effects were durable, with only a 7% decline in C-peptide levels observed at Week 52. Icovamenib was well tolerated, and the company plans to advance its type 1 diabetes program further.

Read more →
BMEA
Mar 31, 2026
BMEAPhases
▲ +15.9%on this news

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion has announced the dosing of its first patient in the Phase II clinical programs, COVALENT-211 and COVALENT-212, which target type 2 diabetes patients not achieving glycemic control with standard therapies. These studies assess the investigational drug icovamenib, anticipated to deliver topline data by the end of 2026. The trials focus on patients requiring improved glucose management, demonstrating previously observed durability in response. This marks a critical advancement for Biomea as it looks to address unmet medical needs in diabetes treatment.

Read more →
BMEA
Mar 24, 2026
BMEAPhases

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Biomea Fusion reported its financial results for the year ending December 31, 2025, highlighting the initiation of two Phase II trials for icovamenib in type 2 diabetes and the completion of a 52-week follow-up from a previous trial. The company anticipates data readouts from multiple ongoing studies in 2026, while maintaining a cash runway into early 2027. Despite a net loss, the company is optimistic about its clinical advancements.

Read more →

About Biomea Fusion, Inc.

San Carlos, CA 34 employees biomeafusion.com
Headquarters1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
BIOPHARMAWATCH ELITE
Trade the next BMEA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime